Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20514065 | 0.81 | SMN1; SMN2 (0.45) | ALDH1A1GLAGAALMNAHTT | |
| SCHEMBL10947527 | 0.79 | — | — | |
| SCHEMBL7784530 | 0.74 | ALDH1A1 (0.47) | ATMALDH1A1TDP1GLAGAA | |
| SCHEMBL11101832 | 0.69 | — | — | |
| SCHEMBL10566600 | 0.68 | SMN1; SMN2 (0.38) | ATMALDH1A1TDP1GLALMNA | |
| SCHEMBL10876978 | 0.67 | — | — | |
| SCHEMBL6964169 | 0.67 | GLA (0.32) | ATMALDH1A1TDP1GLA | |
| SCHEMBL11650232 | 0.66 | GLA (0.41) | ATMALDH1A1TDP1GLAGAA | |
| SCHEMBL6328557 | 0.64 | TSHR (0.52) | ALDH1A1GAALMNAHTT | |
| SCHEMBL16229967 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817305-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | PIRAMAL ENTPR LTD (IN) | 2016-09-28 | — | — | EP | claimed |
| US-20160031867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2016-02-04 | — | — | US | claimed |
| EP-2817305-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | EP | claimed |
| WO-2013124823-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2013-08-29 | — | — | WO | claimed |
| EP-2817305-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | PIRAMAL ENTPR LTD (IN) | 2016-09-28 | — | — | EP | disclosed |
| US-20160031867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2016-02-04 | — | — | US | disclosed |
| US-20160031867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2016-02-04 | — | — | US | disclosed |
| EP-2817305-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | EP | disclosed |
| EP-2817305-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013124823-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013124823-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2013-08-29 | — | — | WO | disclosed |
| EP-1338592-B1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20030166616-A1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1338592-A1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242399-A1 | $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB S.A. (BE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001046167-A1 | α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB, S.A. (BE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110958-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166616-A1 | Novel 2-phenylpiperazine derivatives | VIPR2, BDKRB2, TRPC5 | ATM 4301/4885ALDH1A1 3627/4885TDP1 4362/4885 |
| US-20160031867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | HRH1, HRH2, HRH3 | ATM 2985/4885ALDH1A1 856/4885TDP1 2578/4885 |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | ATM 2521/4885ALDH1A1 732/4885TDP1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.